Humacyte, Inc. (NASDAQ:HUMA) Q4 2023 Earnings Conference Call March 22, 2024 8:00 AM ET

Company Participants

Lauren Marek - Investor Relations, LifeSci Advisors
Laura Niklason - President and Chief Executive Officer
Dale Sander - Chief Financial Officer and Chief Corporate Development Officer

Conference Call Participants

Ryan Zimmerman - BTIG
Kristen Kluska - Cantor Fitzgerald & Co.
Joshua Jennings - TD Cowen
Allison Bratzel - Piper Sandler
Vernon Bernardino - H.C. Wainwright

Operator

Good morning, ladies and gentlemen, and welcome to the Humacyte 2023 Fourth Quarter Year-End Results Conference Call. Currently, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. As a reminder, this conference call is being recorded.

I will now turn the call over to Lauren Marek with LifeSci Advisors. Please go ahead.

Lauren Marek

Thank you, operator. Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under U.S. federal securities laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ from statements made on this call is contained in our periodic reports filed with the SEC.

The forward-looking statements made during this call speak only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, except as required by law. Information presented on this call is contained in the press release we issued this morning and in our Form 10-K, which after filing may be accessed from the Investors page of the Humacyte website.

Joining me on today's call from Humacyte are Dr. Laura Niklason, President and Chief Executive Officer; Dale Sander, Chief Financial Officer and Chief Corporate Development Officer; and Dr. Heather Prichard, Chief Operating Officer. Dr. Niklason will provide a summary of the Company's progress during the year and recent weeks, and Dale will review the Company's financial results for the quarter and year ended December 31, 2023. Following their prepared remarks, the management team will be available for your questions.

I will now turn the call over to Dr. Niklason.

Laura Niklason

Thank you, Lauren. Good morning, everyone, and thank you for joining us for our 2023 financial results and business update call. Our fourth quarter and the start of 2024 have been highly productive for Humacyte. Importantly, Humacyte completed submission of our BLA in December, and the FDA accepted our biologics license application for the HAV in the vascular trauma indication in February of this year.